731 related articles for article (PubMed ID: 34706925)
1. Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G; Krauthamer M; Bjalme-Evans M
J Investig Med; 2022 Jan; 70(1):5-13. PubMed ID: 34706925
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
Amaro A; Sugimoto D; Wharton S
Postgrad Med; 2022 Jan; 134(sup1):5-17. PubMed ID: 36691309
[TBL] [Abstract][Full Text] [Related]
3. Clinical review of subcutaneous semaglutide for obesity.
Phillips A; Clements JN
J Clin Pharm Ther; 2022 Feb; 47(2):184-193. PubMed ID: 34964141
[TBL] [Abstract][Full Text] [Related]
4. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
[No Abstract] [Full Text] [Related]
5. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D; Abrahamsson N; Davies M; Hesse D; Greenway FL; Jensen C; Lingvay I; Mosenzon O; Rosenstock J; Rubio MA; Rudofsky G; Tadayon S; Wadden TA; Dicker D;
JAMA; 2021 Apr; 325(14):1414-1425. PubMed ID: 33755728
[TBL] [Abstract][Full Text] [Related]
6. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M; Færch L; Jeppesen OK; Pakseresht A; Pedersen SD; Perreault L; Rosenstock J; Shimomura I; Viljoen A; Wadden TA; Lingvay I;
Lancet; 2021 Mar; 397(10278):971-984. PubMed ID: 33667417
[TBL] [Abstract][Full Text] [Related]
7. Semaglutide for Weight Loss: Was It Worth the Weight?
Novograd J; Mullally J; Frishman WH
Cardiol Rev; 2022 Nov-Dec 01; 30(6):324-329. PubMed ID: 36201244
[TBL] [Abstract][Full Text] [Related]
8. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.
Ard J; Fitch A; Fruh S; Herman L
Adv Ther; 2021 Jun; 38(6):2821-2839. PubMed ID: 33977495
[TBL] [Abstract][Full Text] [Related]
9. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Wadden TA; Bailey TS; Billings LK; Davies M; Frias JP; Koroleva A; Lingvay I; O'Neil PM; Rubino DM; Skovgaard D; Wallenstein SOR; Garvey WT;
JAMA; 2021 Apr; 325(14):1403-1413. PubMed ID: 33625476
[TBL] [Abstract][Full Text] [Related]
10. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
Cowart K
Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
[No Abstract] [Full Text] [Related]
11. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
[TBL] [Abstract][Full Text] [Related]
12. Semaglutide as a promising antiobesity drug.
Christou GA; Katsiki N; Blundell J; Fruhbeck G; Kiortsis DN
Obes Rev; 2019 Jun; 20(6):805-815. PubMed ID: 30768766
[TBL] [Abstract][Full Text] [Related]
13. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Moiz A; Levett JY; Filion KB; Peri K; Reynier P; Eisenberg MJ
Am J Cardiol; 2024 Jul; 222():121-130. PubMed ID: 38679221
[TBL] [Abstract][Full Text] [Related]
15. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
Isaacs D; Prasad-Reddy L; Srivastava SB
Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.
Lau DCW; Batterham RL; le Roux CW
Expert Rev Clin Pharmacol; 2022 Mar; 15(3):251-267. PubMed ID: 35466848
[TBL] [Abstract][Full Text] [Related]
17. [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
Scheen AJ
Rev Med Liege; 2019 Sep; 74(9):488-494. PubMed ID: 31486321
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH
Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305
[TBL] [Abstract][Full Text] [Related]
19. Semaglutide 2.4-mg injection as a novel approach for chronic weight management.
Kyrillos J
Am J Manag Care; 2022 Dec; 28(15 Suppl):S297-S306. PubMed ID: 36525677
[TBL] [Abstract][Full Text] [Related]
20. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]